FDA Approves AVLAYAH for Hunter Syndrome as First Biologic to Cross 4-Nanometer Brain Barrier
Updated
Updated · ScienceBlog.com · Jul 18
FDA Approves AVLAYAH for Hunter Syndrome as First Biologic to Cross 4-Nanometer Brain Barrier
1 articles · Updated · ScienceBlog.com · Jul 18
Summary
AVLAYAH won FDA approval in March 2026 as the first biologic designed to cross the blood-brain barrier, allowing enzyme replacement therapy to reach the brains of children with Hunter syndrome.
More than 98% of small-molecule drugs and virtually all large biologics are blocked by the barrier’s tightly sealed endothelial junctions, leaving traditional Hunter treatments able to clear disease in the body but not the brain.
AVLAYAH works by exploiting receptor-mediated transcytosis, binding the transferrin receptor that normally ferries iron into the brain and using that route to shuttle its therapeutic enzyme across.
The approval highlights a broader shift in neurology toward barrier-penetrating therapies, alongside small molecules such as ALS candidate XL20 and AI-guided drug design aimed at improving brain delivery.
That delivery problem has long constrained neurology even as Alzheimer’s deaths have risen more than 140% since 2000, making blood-brain-barrier access a central target for future CNS drugs.
After a major Parkinson's trial failure, is this celebrated brain-delivery platform truly a master key for all neurological diseases?
With a one-time gene therapy on the horizon, is this new lifelong treatment already facing obsolescence?
Could hijacking the brain's iron pathway with 'Trojan Horse' drugs create unforeseen long-term risks?
AVLAYAH™ Wins Historic FDA Accelerated Approval: Transforming Hunter Syndrome Treatment and Brain Drug Delivery
Overview
Denali Therapeutics made history with the FDA approval of AVLAYAH™, the first biologic for Hunter syndrome that can cross the blood-brain barrier and directly treat neurological symptoms. This breakthrough was made possible by Denali’s TransportVehicle™ platform, which uses a natural brain transport system to deliver the therapeutic enzyme into the central nervous system. Clinical trials showed strong biochemical improvements, leading the FDA to grant accelerated approval based on these results. AVLAYAH offers new hope for children with Hunter syndrome, addressing a long-standing unmet need and opening the door for future brain-targeted therapies for other rare and neurodegenerative diseases.